|
|
News Breaks | | | | June 15, 2012 | | 14:54 EDT |  | ARNA | Arena volatility elevated into PDUFA Arena July put option implied volatility of 175, October is at 153, January is at 133; compared to its 26-week average of 142 according to Track Data, suggesting larger near term price movement ahead of the June 27 PDUFA date on obesity drug on lorcaserin. | |
|
News For ARNA From The Last 14 Days Check below for free stories on ARNA the last two weeks. |
|
|
| June 14, 2013 | | 08:11 EDT |  | ARNA | Arena Pharmaceuticals management to meet with Leerink
Subscribe for More Information | | | June 11, 2013 | | 05:56 EDT |  | ARNA | Arena Pharmaceuticals price target raised to $12.50 from $9 at Piper Jaffray
Subscribe for More Information | | | June 7, 2013 | | 09:27 EDT |  | ARNA | On The Fly: Pre-market Movers HIGHER: Concurrent (CCUR), up 9.2% after doubling its dividend... Christopher & Banks (CBK), up 9.1% after quarterly earnings, revenue beat expectations... Gamestop (GME), up 2.5% after Microsoft (MSFT) clarifies how games licensing will works on upcoming Xbox One system... Arena (ARNA), up 1.7% after saying Belviq weight-loss drug available in U.s. next week, triggering milestone payment. LOWER: TiVo (XXX), down 18.7% after announcing patent litigation with Google's (GOOG) Motorola, Cisco (CSCO) and Time Warner Cable (TWC), doubles stock buyback authorization... Iron Mountain (IRM), down 17.2%, Lamar Advertising (LAMR), down 8.3%, Equinix (EQIX), down 7.8%, CBS (CBS), down 2.1%, after IRS forms working group on REIT issues, which could delay some of those companies plans for or consideration of REIT conversion... Intel (INTC), down 0.8% following downgrade to Underweight at Piper Jaffray. | | | 08:17 EDT |  | ARNA | Arena says BELVIQ available in U.S. pharmacies within one week
Subscribe for More Information | | | 08:17 EDT |  | ARNA | Arena Pharmaceuticals achieves $65M in milestones with Belviq U.S. launch
| | | 08:16 EDT |  | ARNA | Arena says BELVIQ available in U.S. pharmacies within one week
Subscribe for More Information | |
|
|
|
|
|
|